CEVEC Pharmaceuticals and InVivo BioTech Services have signed a strategic license agreement. The license enables InVivo to use the proprietary CAP-T transient expression system. CAP-T Technology is based
New data published by Novartis, show that patients with advanced neuroendocrine tumors (NET) of the midgut who were treated with Sandostatin LAR Depot (octreotide acetate for injectable suspension)
Caleco Pharma has signed a letter of intent with Caleco Pharma Europe (SL), a Spanish corporation. The Letter of Intent sets out the proposed terms of a License
Takeda will establish four new commercial subsidiaries covering Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. The new subsidiaries – Takeda Pharmaceuticals Mexico, Takeda Pharmaceuticals Trade (Turkey), Takeda
Sanofi-Aventis has signed a binding agreement for the acquisition of Fovea Pharmaceuticals (Fovea) a privately held French research and development biopharmaceutical company, focused on ocular diseases. Under the
Sciele Pharma and Addrenex Pharmaceuticals have announced that Addrenex has submitted a supplemental New Drug Application (sNDA) to the FDA for Clonicel (modified-release clonidine) to treat attention deficit
Sanofi-Aventis and Merrimack Pharmaceuticals have announced a global collaboration and licensing agreement on MM-121, a first-in-class, fully human monoclonal antibody designed to block signaling of the ErbB3 (HER3)
Cell Therapeutics (CTI) has announced that in a study from Brown University, patients with cancer of the lower esophagus demonstrated a high rate of complete remission (CR) when
Onset Therapeutics has launched BenzEFoam (benzoyl peroxide) 5.3% Emollient Foam, the first prescription foam formulation of benzoyl peroxide. BenzEFoam Emollient Foam is indicated for the topical treatment of
Advaxis’s Vaccine candidate ADXS11-001, in phase I trial has shown 36 month survival in 3 of the 13 evaluable patients treated with the cancer vaccine (ADXS11-001), indicating the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.